At a glance

ClinicalIndex Comparison Record

Phase 4Completed· 52 enrolled

Drug / intervention

Pramipexoledrug

Likely dose

Pramipexole 0.125 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02033369

NCT02033369Phase 4Completed

Compare CT.gov

Ventrostriatal Dopamine Release and Reward Motivation in MDD

New York State Psychiatric Institute·interventional·Posted Jan 10, 2014·Updated Nov 1, 2019

In Brief

A Phase 4 clinical trial evaluating Pramipexole for Major Depressive Disorder. Completed, enrolled 52 participants across 1 site.

Detailed Summary

This study aims to determine whether ventral striatal dopamine release is a mechanism of reward motivation in major depression, whether dopamine release is low in depression, and whether DA release and reward motivation predict response to dopamine-targeted treatment with pramipexole.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsMajor Depressive Disorder

CountriesUnited States

CollaboratorsColumbia University, Research Foundation for Mental Hygiene, Inc., Mclean Hospital, Icahn School of Medicine at Mount Sinai, National Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished

2014201520162017201820192020202120222023202420252026

First PostedJan 2014

Enrollment StartFeb 2014

Primary CompletionDec 2016

Study CompletionJul 2017

TodayJul 2026

First PostedJan 10, 2014

Enrollment StartFeb 1, 2014

Primary CompletionDec 1, 2016

Study CompletionJul 1, 2017

TodayJul 2, 2026

Enrollment to primary: 2.8 yearsPosted 12.5 years ago

Interventions

Pramipexoledrug

Dose will be started at 0.125 mg bid, and increased by 0.25 mg/day every 3-4 days to a target range of 1.0 - 2.5 mg/day.